{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:58:50Z","timestamp":1793051930498,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004738","name":"E-Da Hospital","doi-asserted-by":"publisher","award":["EDAHS111029"],"award-info":[{"award-number":["EDAHS111029"]}],"id":[{"id":"10.13039\/501100004738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jhepr.2022.100617","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:25:23Z","timestamp":1666985123000},"page":"100617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-2414","authenticated-orcid":false,"given":"Cheng-Hao","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Haw","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-9134","authenticated-orcid":false,"given":"Jia-Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-4163","authenticated-orcid":false,"given":"John A.","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Town","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-5103","authenticated-orcid":false,"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100617_bib1","unstructured":"World Health Organization. Hepatitis B. [Internet] [cited; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.jhepr.2022.100617_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.jhepr.2022.100617_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2022.100617_bib4","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir\u2014a propensity score\u2013matched study","volume":"219","author":"Nguyen","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib10","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100617_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","article-title":"Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib14","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/infdis\/jiy697","article-title":"The incidence of hepatitis B surface antigen loss between hepatitis B E antigen-negative noncirrhotic patients who discontinued or continued entecavir therapy","volume":"219","author":"Chen","year":"2019","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib15","first-page":"1629","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100617_bib16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.30474","article-title":"The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cgh.2021.08.037","article-title":"Severe acute exacerbation after cessation of nucleos(t)ide analog for chronic hepatitis B: a real-world study of routine practice","volume":"20","author":"Hsu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100617_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/liv.14330","article-title":"The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B","volume":"40","author":"Wong","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1136\/gutjnl-2021-326232","article-title":"Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities","volume":"71","author":"Hsu","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100617_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.jhepr.2022.100617_bib25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1634\/theoncologist.2018-0043","article-title":"Meta-research on oncology trials: a toolkit for researchers with limited resources","volume":"23","author":"Riechelmann","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2022.100617_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2005468","article-title":"Meta-research: why research on research matters","volume":"16","author":"Ioannidis","year":"2018","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jhepr.2022.100617_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/liv.15140","article-title":"Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies","volume":"42","author":"Liu","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2022.100617_bib29","unstructured":"GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2020 March 1]; Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.jhepr.2022.100617_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S2468-1253(19)30015-9","article-title":"Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials","volume":"4","author":"Buti","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib31","article-title":"Cessation of nucleos(t)ide analogue therapy in non-cirrhotic hepatitis B patients with prior severe acute exacerbation","volume":"10","author":"Lai","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2022.100617_bib32","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100617_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100617_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2008.10.017","article-title":"Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy","volume":"50","author":"Shouval","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jvh.12851","article-title":"The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients","volume":"25","author":"Chen","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100617_bib36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhepr.2022.100617_bib38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jvh.13526","article-title":"Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B","volume":"28","author":"Chen","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100617_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12876-017-0697-3","article-title":"Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy","volume":"17","author":"Chien","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100617_bib40","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","article-title":"Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy","volume":"18","author":"Chiu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib41","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1007\/s10620-021-07128-6","article-title":"Predictors of virological suppression after clinical relapse in patients who discontinued entecavir or tenofovir","volume":"67","author":"Fang","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2022.100617_bib42","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/jgh.13728","article-title":"Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy","volume":"32","author":"Hsu","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvh.13528","article-title":"The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients","volume":"28","author":"Huang","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100617_bib44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100617_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222221","article-title":"Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100617_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2022.100617_bib49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100617_bib50","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib51","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib52","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41598-017-02010-w","article-title":"Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg \u2264 200 IU\/mL","volume":"7","author":"Yao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2022.100617_bib53","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/apt.13409","article-title":"Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis","volume":"42","author":"Chen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100617_bib54","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s10620-015-3775-9","article-title":"Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir","volume":"60","author":"Fong","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2022.100617_bib55","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib56","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100617_bib57","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.2147\/IJGM.S321253","article-title":"Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B","volume":"14","author":"Liao","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.jhepr.2022.100617_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.kjms.2015.11.005","article-title":"Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients","volume":"32","author":"Lin","year":"2016","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jhepr.2022.100617_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14654","article-title":"Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues","volume":"41","author":"Manolakopoulos","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/liv.15128","article-title":"Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: a multicentre cohort study","volume":"42","author":"Papatheodoridi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100617_bib61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.29497","article-title":"Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100617_bib62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/1471-2334-14-439","article-title":"Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs","volume":"14","author":"Sohn","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib63","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib64","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/ajg.2016.109","article-title":"Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg","volume":"111","author":"Wang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100617_bib65","article-title":"Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: a prospective randomized cohort study","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhepr.2022.100617_bib66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment","volume":"54","author":"Xia","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100617_bib67","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg < 100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100617_bib68","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.dld.2021.12.017","article-title":"On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty","volume":"54","author":"Broquetas","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib69","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with\u00a0low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100617_bib70","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/infdis\/jiab596","article-title":"Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients","volume":"225","author":"Chen","year":"2022","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100617_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.15966","article-title":"A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: an observational study","author":"Peng","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhepr.2022.100617_bib72","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/jvh.13729","article-title":"Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy","volume":"Nov;29","author":"Papatheodoridi","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2022.100617_bib73","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100617_bib75","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922001896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922001896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:29:35Z","timestamp":1762900175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922001896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2589555922001896"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100617","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100617"}}